Condition
Clear-cell Renal Cell Carcinoma
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Withdrawn1
Terminated1
Completed1
Not Yet Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07243067Not Yet Recruiting
Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer
NCT04518046Phase 1CompletedPrimary
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
NCT03035630Phase 2WithdrawnPrimary
Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
NCT02837991Phase 1Terminated
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
Showing all 4 trials